Incidence of second primary cancers among survivors of childhood cancer: A population-based study, Osaka, Japan, 1975-2015.
cancer registry
childhood cancer
population-based analysis
second primary cancer
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
revised:
20
10
2022
received:
21
06
2022
accepted:
27
10
2022
pubmed:
9
11
2022
medline:
8
3
2023
entrez:
8
11
2022
Statut:
ppublish
Résumé
Second primary cancer (SPC) is one of the most life-threatening late effects of childhood cancers. We investigated the incidence and survival outcomes of SPC in childhood cancer patients in Japan. Data were obtained from the population-based Osaka Cancer Registry. Individuals diagnosed with cancer at age 0-14 years during 1975-2014 and survived 2 months or longer were followed through December 2015. The risk of developing SPC was assessed with standardized incidence ratio (SIR), excess absolute risk (EAR, per 100,000 person-years), and cumulative incidence. Multivariable Poisson regression analysis was carried out to assess relative risks of SPC by treatment method. Survival analysis was undertaken using the Kaplan-Meier method. Of 7229 childhood cancer survivors, 101 (1.4%) developed SPC after a median of 11.6 years. Overall SIR was 5.0, which corresponded with 84.3 EAR. The cumulative incidence was 0.9%, 2.1%, and 3.4% at 10, 20, and 30 years, respectively. Among all SPCs, the type that contributed most to the overall burden was cancers in the central nervous system (EAR = 28.0) followed by digestive system (EAR = 15.1), thyroid (EAR = 8.3), and bones and joints (EAR = 7.8); median latency ranged from 2.0 years (lymphomas) to 26.6 years (skin cancers). Patients treated with radiotherapy alone were at a 2.58-fold increased risk of developing SPC compared to those who received neither chemotherapy nor radiotherapy. Among patients who developed SPCs, 5-year and 10-year survival probabilities after SPC diagnosis were 61.7% and 52.0%, respectively. Risk-based long-term follow-up planning is essential to inform survivorship care and help reduce the burden of SPCs in childhood cancer survivors.
Identifiants
pubmed: 36345911
doi: 10.1111/cas.15640
pmc: PMC9986077
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1142-1153Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP20K18952
Organisme : Japan Society for the Promotion of Science
ID : JP22K10548
Organisme : Ministry of Health, Labour and Welfare
ID : 20EA1026
Organisme : Ministry of Health, Labour and Welfare
ID : H30-Gantaisaku-Ippan-009
Informations de copyright
© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Blood. 2005 May 15;105(10):3802-11
pubmed: 15687239
Cancer Sci. 2021 Mar;112(3):1150-1160
pubmed: 33428808
Transl Pediatr. 2014 Apr;3(2):156-82
pubmed: 26835334
Nat Commun. 2017 Aug 4;8(1):186
pubmed: 28775249
Int J Cancer. 2007 Nov 15;121(10):2233-40
pubmed: 17557301
Cancer Sci. 2018 Feb;109(2):422-434
pubmed: 29178401
Int J Cancer. 2022 Jun 15;150(12):1941-1947
pubmed: 35080783
Pediatr Blood Cancer. 2018 Aug;65(8):e27103
pubmed: 29719120
Am Soc Clin Oncol Educ Book. 2014;:e57-67
pubmed: 24857148
J Cancer Educ. 2016 Sep;31(3):430-42
pubmed: 25948413
JAMA Oncol. 2019 Mar 1;5(3):318-325
pubmed: 30570657
Br J Cancer. 1989 May;59(5):792-6
pubmed: 2736215
PLoS One. 2018 Nov 15;13(11):e0207243
pubmed: 30440007
BMC Cancer. 2011 Feb 23;11:83
pubmed: 21342533
J Clin Oncol. 2009 May 10;27(14):2328-38
pubmed: 19332714
N Engl J Med. 1996 Mar 21;334(12):745-51
pubmed: 8592547
Blood. 2009 Jan 29;113(5):1175-83
pubmed: 18971419
Blood. 2009 May 14;113(20):4992-5001
pubmed: 19264919
J Natl Cancer Inst. 2001 Apr 18;93(8):618-29
pubmed: 11309438
J Formos Med Assoc. 2022 Jan;121(1 Pt 2):350-359
pubmed: 34154895
Semin Oncol. 2008 Aug;35(4):418-29
pubmed: 18692692
EJC Suppl. 2014 Jun;12(1):5-17
pubmed: 26217162
J Nippon Med Sch. 2019 Sep 3;86(4):207-214
pubmed: 31061250
IARC Sci Publ. 1987;(82):1-406
pubmed: 3329634
Gynecol Oncol. 2018 Nov;151(2):190-195
pubmed: 30268525
Int J Clin Oncol. 2016 Jun;21(3):506-16
pubmed: 26620038
Br J Cancer. 2004 Nov 29;91(11):1905-10
pubmed: 15534607
Lancet Oncol. 2017 Jun;18(6):719-731
pubmed: 28410997
Cancer. 1991 Jan 1;67(1):193-201
pubmed: 1985716
Arch Intern Med. 1999 Dec 13-27;159(22):2713-9
pubmed: 10597762
Int J Cancer. 1998 Jul 29;77(3):370-7
pubmed: 9663598
Radiat Res. 1998 Jun;149(6):625-30
pubmed: 9611101
Int J Clin Oncol. 2022 Jan;27(1):7-15
pubmed: 34779960
J Clin Oncol. 2015 Nov 1;33(31):3531-2
pubmed: 26261248
JAMA. 2011 Jun 8;305(22):2311-9
pubmed: 21642683
J Clin Oncol. 2007 Jul 1;25(19):2833-9
pubmed: 17602088
Lancet. 2005 Jun 11-17;365(9476):2014-23
pubmed: 15950715
Br J Cancer. 1999 Apr;79(11-12):1884-93
pubmed: 10206309
Pediatr Blood Cancer. 2007 Apr;48(4):453-9
pubmed: 16767718
BMJ. 1992 Apr 11;304(6832):951-8
pubmed: 1581717
J Clin Oncol. 2009 May 10;27(14):2356-62
pubmed: 19255307
Blood. 2007 Jan 1;109(1):46-51
pubmed: 16985182
J Natl Cancer Inst. 2010 Jul 21;102(14):1083-95
pubmed: 20634481
Pediatr Blood Cancer. 2006 Nov;47(6):811-8
pubmed: 16317745
Pediatr Blood Cancer. 2006 Feb;46(2):135-42
pubmed: 16369921
Childs Nerv Syst. 2008 Jul;24(7):793-805
pubmed: 18392837
J Clin Oncol. 2011 Aug 1;29(22):3056-64
pubmed: 21709189
Cancer Sci. 2023 Mar;114(3):1142-1153
pubmed: 36345911